BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 18567793)

  • 1. Systems-level analysis of ErbB4 signaling in breast cancer: a laboratory to clinical perspective.
    Chuu CP; Chen RY; Barkinge JL; Ciaccio MF; Jones RB
    Mol Cancer Res; 2008 Jun; 6(6):885-91. PubMed ID: 18567793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.
    Junttila TT; Sundvall M; Lundin M; Lundin J; Tanner M; Härkönen P; Joensuu H; Isola J; Elenius K
    Cancer Res; 2005 Feb; 65(4):1384-93. PubMed ID: 15735025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.
    Naresh A; Long W; Vidal GA; Wimley WC; Marrero L; Sartor CI; Tovey S; Cooke TG; Bartlett JM; Jones FE
    Cancer Res; 2006 Jun; 66(12):6412-20. PubMed ID: 16778220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5.
    Long W; Wagner KU; Lloyd KC; Binart N; Shillingford JM; Hennighausen L; Jones FE
    Development; 2003 Nov; 130(21):5257-68. PubMed ID: 12954715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
    Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
    Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Wwox with ErbB4 in breast cancer.
    Aqeilan RI; Donati V; Gaudio E; Nicoloso MS; Sundvall M; Korhonen A; Lundin J; Isola J; Sudol M; Joensuu H; Croce CM; Elenius K
    Cancer Res; 2007 Oct; 67(19):9330-6. PubMed ID: 17909041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.
    Junttila TT; Laato M; Vahlberg T; Söderström KO; Visakorpi T; Isola J; Elenius K
    Clin Cancer Res; 2003 Nov; 9(14):5346-57. PubMed ID: 14614020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
    Tang CK; Concepcion XZ; Milan M; Gong X; Montgomery E; Lippman ME
    Cancer Res; 1999 Oct; 59(20):5315-22. PubMed ID: 10537315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.
    Ariazi EA; Clark GM; Mertz JE
    Cancer Res; 2002 Nov; 62(22):6510-8. PubMed ID: 12438245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
    Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
    Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms.
    Hollmén M; Määttä JA; Bald L; Sliwkowski MX; Elenius K
    Oncogene; 2009 Mar; 28(10):1309-19. PubMed ID: 19151766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
    DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
    J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M; Grijalva R; Yu D
    Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
    Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
    Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities.
    Vidal GA; Clark DE; Marrero L; Jones FE
    Oncogene; 2007 Jan; 26(3):462-6. PubMed ID: 16832345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.